May 15, 2020

Creoptix Supporting COVID-19 Research

Committed to enabling hospitals and clinical researchers with high performance solutions to characterize binding affinity and kinetics of antibodies on SARS-CoV-2

Collaboration

We are committed to enabling hospitals and clinical researchers with high performance solutions to characterize binding affinity and kinetics of antibodies on SARS-CoV-2 in conditions closer to real-life. "The WAVEsystem's combination of sensitivity and robustness may prove crucial in shedding light on antibody binding in serum and plasma,” said our CEO Line Stigen Raquet at a recent interview with Private Equity Wire.

More information here